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The world is facing an impending epidemic of 
diabetes [1]. Diabetes occurs in two forms – Type 1 
and Type 2. These are separate entities, although 
they share an elevation of fasting plasma glucose 
(≥7.0 mM or 126 mg/dl) as the only required 
diagnostic criterion. The diabetes epidemic can be 
attributed to Type 2 Diabetes. Historically, Type 2 
Diabetes has been a disease of the aged population. 
Recently, a drift in the incidence is observed, with 
younger individuals developing Type 2 Diabetes. 
 
Concurrently, life expectancy in the world is increasing 
[2, 3]. This implies that health care will have to deal 
with an increased prevalence of diseases afflicting 
people of higher age. Aging is a well-established risk 
factor for Type 2 Diabetes. Pathogenetic processes 
linked to aging are thought to play a major role in 
development of the disease. Type 2 Diabetes arises as 
impaired insulin sensitivity of the peripheral target 
tissues of insulin, i.e., skeletal muscle, liver and adipose 
tissue, combines with insufficient insulin secretion. It is 
widely embraced that both insulin secretion and insulin 
sensitivity are reduced in the aged. Thus, in the insulin-
resistant individual, insulin secretion, in the genetically 
predisposed, can not overcome impaired action of 
insulin. This results in elevated plasma glucose, the 
hallmark of diabetes.  
 
In the recent years, global and unbiased analyses of 
genetic variability in large cohorts of patients with Type 
2 Diabetes and individuals with metabolic traits have 
changed how we perceive the pathogenesis of Type 2 
Diabetes [4]. These studies are known as genome-wide 
association studies (GWAS) and have now generated in 
excess of 50 genes, which are firmly linked to Type 2 
Diabetes or  relevant metabolic  traits [5].   This  list   of  
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genes is continuously expanded. Perhaps the greatest 
insight from these studies is that the vast majority of 
genes associated with Type 2 Diabetes seem to be 
relevant for the function of the insulin-secreting β-cell 
[6]. β-cells are located in the islets of Langerhans, the 
endocrine portion of the pancreas. They sense plasma 
glucose levels and secrete insulin. The hormone controls 
whole body metabolism by stimulating glucose uptake in 
skeletal muscle and adipose tissue, while inhibiting 
glucose production from the liver. In fact, some of the 
associated genes identified by the GWAS could be 
envisioned to play a role in control of the β-cell. This 
would, at least in part, determine the insulin-secretory 
capacity in a given individual. The genes include 
CDKN2A/B and CDKAL1, which are involved in cell 
cycle regulation, IGF2BP2,  HHEX/IDE and, 
CDC123/CAMK1D, which are implicated in growth as 
well as a host of transcription factors such as TCF7L2, 
NOTCH2, and HNF1B ( TCF2), which are thought to 
control β-cell development. While the GWAS have lent 
support to the critical role of β-cell mass in the 
development of Type 2 Diabetes, its importance has been 
hotly debated over the years. Currently, a view is favored 
where insufficient adaptation of β-cell mass to insulin 
resistance plays a pathogenetic role. This is supported by 
extensive analyses of autopsy-derived pancreatic 
specimens from patients with Type 2 Diabetes [7, 8].   
 
In this issue of Aging, Kuhlow and colleagues report 
data, which fill in a gap in our understanding of the 
pathogenesis of Type 2 Diabetes, aging and control of 
β-cell mass [9]. They describe studies in which 
telomerase deficiency in mice results in perturbed 
glucose metabolism due to an impairment of insulin 
secretion. The enzyme telomerase is responsible for the 
extension of chromosome ends with repeated DNA 
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telomere and allow faithful replication of DNA at the 
chromosomal ends. However, when telomeres are 
shortened, which is known to occur with age, DNA 
replication is thought to slow down, ultimately leading 
to senescence of cells. For this reason, telomeres have 
been implicated in research on senescence and aging. 
Also in diabetes research, telomere shortening has been 
linked with Type 2 Diabetes [10]. Some work has 
addressed a possible role of telomerase in β-cell 
regeneration [11]. However, for the most part, these 
links have been found when analyzing telomere length 
in circulating leukocytes in patient cohorts. A 
shortcoming of such studies is that we are not provided 
with any information about telomere length in the actual 
cells and tissues involved in metabolic homeostasis. 
Kuhlow and colleagues bring a new perspective to the 
research field, since they examined telomere length in 
the relevant tissue, the pancreatic islets.  
  
The gene for the reverse-transcriptase part of 
telomerase, Terc, was targeted (Terc -/-) in mice [9]. 
The Terc -/- mice were normoglycemic and exhibited 
unaltered insulin levels in the basal state. However, 
upon a challenge with glucose, the sugar was eliminated 
at a slower rate in the face of less insulin being released. 
Insulin sensitivity was seemingly unaffected, as 
reflected by in vivo insulin tolerance. This points to 
the  β-cell as the culprit, and was reinforced by the 
finding of reduced average telomere length in islets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The authors proceeded to unravel whether a reduction in 
β-cell mass or function accounted for the deficiency of 
insulin secretion. They found that several parameters 
reflecting  β-cell mass were perturbed in the Terc -/- 
mice. 
 
Although the studies by Kuhlow and colleagues have 
shed new light on the possible role of telomeres in the 
pathogenesis of Type 2 Diabetes, some questions 
remain. At this point, the data indicate that β-cell mass 
is primarily affected by reduced telomerase length. It 
would be interesting to know if also the function of β-
cells was affected. In human Type 2 Diabetes, a 
deficiency of β-cell function must likely add to a 
reduced β-cell mass to create an impairment of insulin 
secretion [8]. Moreover, islets are composed of several 
cell types in addition to β-cells, particularly the 
glucagon-secreting  β-cell. It would be interesting to 
know whether telomere shortening affects this 
important cell type. Also, there are likely to be many 
molecular events linking shortening of telomeres with 
the impaired replication that was observed by Kuhlow 
and colleagues. This deserves further investigation. 
Finally, more information about telomere length in 
human islets and about genetic variation in genes 
relevant to control of telomere length in subjects with 
Type 2 Diabetes should be acquired. Nevertheless, the 
study by Kuhlow and colleagues represents an 
important step towards better understanding of the link 
between aging and Type 2 Diabetes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Aging is a well‐established risk factor for Type 2 Diabetes. Both
insulin secretion and insulin sensitivity, the major pathogenetic processes in Type
2 Diabetes,  become  impaired  with  increasing  age.  Telomere shortening  occurs
with aging. Studies suggest that this process may be linked with impairments of
both insulin secretion and insulin sensitivity.  
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